The UK Health Security Agency (UKHSA) has been updated to support patients the most appropriate antibiotics while protecting future effectiveness The tool is open to the public.
British antibacterial steward ship tools are based on the World Health Organization (WHO) recognition (access, clock, spare) classification system developed to support excellent antibiotics in the world, nation, and world level. Masu.
This recent review, which is applied to all four countries in the UK, was conducted in 2023 according to the WHO, which updates its category.
Find the best treatment for patients
Most patients need to receive access antibiotics in the first instance. This provides the most effective treatment while minimizing the possibility of resistance.
However, in some cases, some patients may need a watch or spare. Antibiotics are the first or second antibiotics shown in a limited number of infectious diseases, and the preliminary antibiotic is a “last resort” or a new antibiotic.
These are carefully monitored and prioritized as the target of the Steward Ship Program for antibacterial drugs to ensure continuous effectiveness.
Change of antibacterial drug management practice
UKHSA’s latest review shows the Ministry of Health Specialist in 4 British State, the use of antibacterial drugs and English surveillance programs, and antibiotics prescriptions, resistance, medical -related infections (APRHAI). The British classification of 90 antibiotics (APRHAI) has been contributed by the advisory group (APRHAI).
The most important change is that all the first -generation Cephalosporin is classified as access compared to the 2019 clock.
This means that patients with specific allergies, such as penicillin, can access wider antibiotics, which are currently showing that they are less likely to develop bacteria than other bacteria.
This change is consistent with 2023, which recognizes classifications but does not require an increase in the use of cephalosporine. All other cephalosporin remains in the clock or spare category.
Be careful of specific antibiotics
In conjunction with UKHSA reviews in 2019, Amoxicillin/Clear Runic acid is monitored in the UK, but is classified as access in 2023, which is recognized in classification.
Amoxicillin/Clearranic acid is a globally important and widely used drug. However, in British settings, experts have determined that the use of bacteria is more likely to develop bacteria compared to other antibiotics.
British recognition classification is an important antibacterial steward ship tool that helps achieve 20 years of British vision, which contains antibacterial drug resistance.
It also supports one of the national goals set in the British national behavior plan from 2024 to 2029 antibacterial drug resistance.
By 2029, the UK aims to achieve 70 % of the total use of antibiotics from the access category of the entire human health care system to maintain the effectiveness. According to the latest evaluation in 2023, this was 64.1 % of England.
Dr. Colin Brown, Deputy Director of UKHSA, explained:
“This review in the UK helps medical experts to select the optional option for patients while maintaining the effectiveness of antibiotics for future use.”
He concluded: “We also support the development of the guidelines for antibiotics and the development of UK goals to work on antibiotics resistance stipulated in the national behavior plan.”
Source link
